PHARNEXT

110 articles about PHARNEXT

• Pharnext Strengthens its Senior Leadership Team with the Appointment of Scott Johnson as VP, Head of Quality

  1/4/2023

  Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Scott Johnson as VP, Head of Quality.

• Pharnext Strengthens its Ties With Néovacs to Secure the Next Steps in its Development

  12/28/2022

  Pharnext SA announces a series of decisions that have been made to secure the next steps in its development with the support of Néovacs, a French biotech company focused on therapeutic vaccines targeting the treatment of autoimmune diseases and support for promising BioTech and MedTech companies, following the financing and strategic support agreement announced by Pharnext on October 3rd, 2022[1].

• Pharnext Announces that Neovacs Has Set Up a Management Trust to Manage the Pharnext Securities Issued and the Rights and Obligations of Neovacs under the Financing Agreement Signed on September 30th

  10/31/2022

  Pharnext SA announces the conclusion of an agreement with Neovacs for the establishment by Neovacs of a management trust, with Equitis Gestion as trustee, to exercise all of the rights and satisfy all of the obligations of the latter as well as manage the Pharnext securities issued by Pharnext respectively to Neovacs and the Trust, respectively, under the OBSA Agreement signed on September 30th, 2022 between Pharnext and Neovacs.

• Pharnext Reports First Half 2022 Financial Results

  10/17/2022

  Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces its financial results for the first half of 2022.

• Pharnext Executes a Financing Agreement with Néovacs for EUR 20.7 million Net to Further Develop PXT3003 for Charcot-Marie-Tooth Disease Type 1A

  10/3/2022

  Pharnext SA announces the signature of a financing agreement, by which Néovacs, a French biotech company focused on therapeutic vaccines targeting the treatment of autoimmune diseases and investment support of promising biotech and medtech companies, undertakes to subscribe to simple obligations to be issued by Pharnext in an issuance program spanning until July 2023, for a total nominal amount of EUR 21,093,800 .

• Pharnext Announces a Reverse Stock Split and Suspension of the Right to Exercise All the Securities Giving Access to Pharnext's Share Capital Including the Conversions of Convertible Bonds

  10/3/2022

  Pharnext SA announces that its Board of Directors decided to perform a reverse stock split on the shares comprising its capital stock whereby one new share with a nominal value of 1 euro will equal 5,000 old shares with a nominal value of 0.0002 euro, as authorized by Shareholders' meeting held on June 17th, 2022 under resolution # 8.

• Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From ‘Real-World’ Digital Lifestyle Study

  9/15/2022

  Pharnext SA announces that findings on the symptom burden of Charcot-Marie-Tooth Disease Type 1A from the ‘Real-World' Digital Lifestyle Study, CMT&Me, will be presented in three poster presentations at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine 2022.

• Pharnext: Findings From 'Real-World' Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease

  9/14/2022

  Pharnext SA announces the publication of symptom burden findings of Charcot-Marie-Tooth Disease Type1A from the ‘Real-World' Digital Lifestyle Study, CMT&Me, in the Journal of Clinical Neuromuscular Disease.

• Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial

  9/12/2022

  Pharnext SA announces that the first patient has been enrolled in the PREMIER Open Label Extension study of PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A in the United States.

• Pharnext Appoints Dr. Rob Quinn as Chief Financial Officer

  9/1/2022

  Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Dr. Rob Quinn as Chief Financial Officer, effective immediately.

• Pharnext Announces a €2.5m Loan Agreement with Néovacs

  8/23/2022

  Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the signing of a €2.5 million loan agreement with Néovacs, a French biotechnology company listed on Euronext Growth Paris.

• Pharnext Appoints Antoine Gravelle as General Counsel

  7/5/2022

  Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Antoine Gravelle as General Counsel, effective July 1st, 2022.

• Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022

  6/28/2022

  Pharnext SA announces that findings on symptoms burden of Charcot-Marie-Tooth Disease Type 1A from the ‘Real-World' Digital Lifestyle Study, CMT&Me, will be presented in three poster presentations at the upcoming International Congress on Neuromuscular Disease 2022.

• Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors

  6/20/2022

  Pharnext SA announces that at its Annual General Meeting on Friday June 17th all key resolutions proposed by the Pharnext Board of Directors were adopted.

• Pharnext Announces Successful Debt Refinancing and New Loan Agreement

  6/8/2022

  Pharnext SA announces that the Company has entered into a fixed-rate loan agreement with Global Tech Opportunities 13, a member of the Alpha Blue Ocean group, for a total amount of up to €12 million with an annual interest rate of 9.5%.

• Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A

  5/30/2022

  Pharnext SA announces it has completed the enrollment of 387 patients in its pivotal Phase III clinical study of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth disease type 1A.

• New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time

  5/16/2022

  Pharnext SA announces new results from the ongoing open-label follow-up extension study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT-FU trial, which followed the first double-blind, placebo controlled Phase III study, the PLEO-CMT trial.

• Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting

  5/5/2022

  Pharnext SA announces that new findings from CMT&Me, a ‘real-world' digital lifestyle study in patients with Charcot-Marie-Tooth diseases, will be presented in three poster presentations at the upcoming Peripheral Nerve Society Annual Meeting.

• Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors

  3/30/2022

  Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces that Joshua Schafer has been appointed as interim Chairman of the Pharnext Board of Directors with immediate effect.

• Pharnext Appoints Valérie Worrall as Chief Financial Officer

  2/15/2022

  Pharnext SA announces the appointment of Valérie Worrall as Chief Financial Officer, effective March 1st, 2022.